Hunterbrook旗下的对冲基金Hunterbrook Capital表示，他们现在看好Hims & Hers的股票，与其6月的做空立场相反，当时他们关注的是该公司在线销售的GLP-1注射剂。The "affordable weight loss pharmaceutical" supplier Hims & Hers rose over 20%, closing at $31.35, exceeding the intraday all-time high of $30.44 set on November 13. The reason is that the institution Hunterbrook Media, which benchmarks against the short sellers Citron, believes that Trump's nomination of Marty Makary as the head of the FDA may benefit Hims & Hers.
On Monday, November 25, Eastern Time, the "affordable weight loss pharmaceutical" supplier $Hims & Hers Health (HIMS.US)$ saw its stock price during regular trading hours soar over 20%, hitting an all-time high.
The reason is that the institution Hunterbrook Media, which benchmarks against the short sellers Citron, released a report on Monday indicating that Trump's nomination of Marty Makary as the head of the FDA may greatly benefit Hims & Hers, as Makary is an executive at Sesame Inc., and both Sesame and Hims & Hers are startup companies selling GLP-1 weight loss pharmaceuticals.
The hedge fund Hunterbrook Capital under Hunterbrook stated that they are now bullish on Hims & Hers' stocks, in contrast to their short position in June, when they were focused on the sale of GLP-1 injectables online by the company.
$Eli Lilly and Co (LLY.US)$tirzepatide and$Novo-Nordisk A/S (NVO.US)$GLP-1 drugs such as semaglutide have important applications in diabetes treatment and weight loss. However, they are facing supply shortages, which presents market opportunities for companies like Hims & Hers that offer similar generic or related compound products. As of last Friday's close, Hims & Hers' stock price has risen over 184.6% year-to-date, and it is expected to achieve the best annual performance since the company went public.
It is worth noting that on November 21 of this year, Hims & Hers' stock price rose by 10.83% due to court documents showing that the FDA needs more time to decide whether to remove eli lilly and co's GLP-1 drug tirzepatide from the shortage list. This postponement of the decision provides Hims & Hers with more market opportunities. Novo-nordisk a/s’s drug semaglutide is still listed as "currently in shortage" by the FDA, while Hims & Hers does not sell the compound tirzepatide drug.
Nevertheless, Wall Street remains cautious about the company. According to data compiled by Bloomberg, more than half of analysts give the company's stocks a "hold" or "sell" rating, while about 40% of analysts recommend buying Hims & Hers' stocks.
Editor / jayden
